TY  - JOUR
AU  - Barbarot, S
AU  - Wollenberg, A
AU  - Silverberg, J I
AU  - Deleuran, M
AU  - Pellacani, G
AU  - Armario-Hita, J C
AU  - Chen, Z
AU  - Shumel, B
AU  - Eckert, L
AU  - Gadkari, A
AU  - Lu, Y
AU  - Rossi, A B
PY  - 2020
DO  - 10.1080/09546634.2020.1750550
UR  - http://hdl.handle.net/10668/15459
T2  - The Journal of dermatological treatment
AB  - Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the persistent underlying inflammatory pathway in atopic dermatitis (AD), is approved for treatment of moderate-to-severe AD in Europe, USA, Japan and several other...
LA  - en
KW  - Adults
KW  - SCORAD
KW  - atopic dermatitis
KW  - dupilumab
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - Dermatitis, Atopic
KW  - Double-Blind Method
KW  - Humans
KW  - Severity of Illness Index
KW  - Treatment Outcome
TI  - Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.
TY  - research article
VL  - 33
ER  -